Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Study to Evaluate Safety and Efficacy of Radiopharmaceutical IR-101 in Patients With Relapsed or Refractory Neuroblastoma

NCT07067346 is registered in ClinicalTrials.gov with Sichuan University as lead sponsor.

NCT NCT07067346
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07067346 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Study to Evaluate Safety and Efficacy of Radiopharmaceutical IR-101 in Patients With Relapsed or Refractory Neuroblastoma
Lead sponsor
Sichuan University
Phase
Phase 1
Overall status
Recruiting
Start date
July 18, 2025
Completion date
June 30, 2026
Enrollment
10 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

neuroblastoma